CN114190459A - Auxiliary blood sugar-reducing tea bag and preparation method thereof - Google Patents
Auxiliary blood sugar-reducing tea bag and preparation method thereof Download PDFInfo
- Publication number
- CN114190459A CN114190459A CN202111575060.2A CN202111575060A CN114190459A CN 114190459 A CN114190459 A CN 114190459A CN 202111575060 A CN202111575060 A CN 202111575060A CN 114190459 A CN114190459 A CN 114190459A
- Authority
- CN
- China
- Prior art keywords
- parts
- tea bag
- blood sugar
- tea
- guava
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 54
- 239000008280 blood Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241001122767 Theaceae Species 0.000 title claims description 79
- 230000001603 reducing effect Effects 0.000 claims abstract description 34
- 241000508269 Psidium Species 0.000 claims abstract description 25
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 24
- 241000208253 Gymnema sylvestre Species 0.000 claims abstract description 24
- 240000000249 Morus alba Species 0.000 claims abstract description 24
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 24
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 claims abstract description 20
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 20
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 20
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 240000005979 Hordeum vulgare Species 0.000 claims description 6
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000004898 kneading Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000010030 glucose lowering effect Effects 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 20
- 102000004877 Insulin Human genes 0.000 abstract description 16
- 108090001061 Insulin Proteins 0.000 abstract description 16
- 229940125396 insulin Drugs 0.000 abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 239000008103 glucose Substances 0.000 abstract description 14
- 210000002966 serum Anatomy 0.000 abstract description 9
- 108010075254 C-Peptide Proteins 0.000 abstract description 8
- 102000051325 Glucagon Human genes 0.000 abstract description 8
- 108060003199 Glucagon Proteins 0.000 abstract description 8
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract description 8
- 229960004666 glucagon Drugs 0.000 abstract description 8
- 230000004060 metabolic process Effects 0.000 abstract description 8
- 230000035622 drinking Effects 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 239000003651 drinking water Substances 0.000 abstract description 5
- 235000020188 drinking water Nutrition 0.000 abstract description 5
- 235000012054 meals Nutrition 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 abstract description 3
- 235000020510 functional beverage Nutrition 0.000 abstract description 3
- 231100000820 toxicity test Toxicity 0.000 abstract description 3
- 238000009602 toxicology test Methods 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 238000012795 verification Methods 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 7
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 235000017784 Mespilus germanica Nutrition 0.000 description 4
- 244000182216 Mimusops elengi Species 0.000 description 4
- 235000000560 Mimusops elengi Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 235000007837 Vangueria infausta Nutrition 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 235000008777 kaempferol Nutrition 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 2
- 241000549954 Gymnema yunnanense Species 0.000 description 2
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 2
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 2
- 235000009498 luteolin Nutrition 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- OWEFQTXQEHYDEJ-UHFFFAOYSA-N 2,3-dihydroxypropanal diphosphono hydrogen phosphate Chemical compound OCC(O)C=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O OWEFQTXQEHYDEJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 102100029795 Sodium-dependent glucose transporter 1 Human genes 0.000 description 1
- 101710181093 Sodium-dependent glucose transporter 1 Proteins 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000009142 chromium supplementation Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 229930183009 gymnemic acid Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- -1 polyphenol compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of health-care food and functional beverage, and particularly relates to an auxiliary blood sugar-reducing tea bag and a preparation method thereof. The invention relates to a tea bag for reducing blood sugar, which is prepared from mulberry leaf tea, gymnema sylvestre, barley grass, guava, honeysuckle flower and wolfberry fruit according to a certain weight proportion. The tea bag has scientific formula, simple preparation process, convenient drinking, safety and reliability, does not show obvious toxic effect on various observation indexes of male and female rats through safety toxicology tests, and can effectively improve various sugar metabolism indexes (including fasting blood glucose, serum insulin level, C peptide, glucagon and the like) of a type 2diabetes model mouse (db/db mouse) through effect verification tests, 1000mL of drinking water is brewed in each tea bag, 200mL of drinking water is drunk before each meal, and the tea bag has ideal auxiliary treatment effect on type 2diabetes patients.
Description
Technical Field
The invention belongs to the technical field of health-care food and functional beverage, and particularly relates to an auxiliary blood sugar-reducing tea bag and a preparation method thereof.
Background
Diabetes Mellitus (DM) is a non-infectious disease of chronic metabolic disorders caused by defects in pancreatic islet function. With the development of economy, the living standard of people is gradually improved, and DM is gradually the third most non-infectious disease in the world after cardiovascular diseases and tumors. The international diabetes union (IDF) website (http:// www.diabetesatlas.org /) published, and the number of DM patients in 2017 worldwide adults is about 4.25 million, wherein the number of DM patients in China is as high as 1.14 million. Chinese guidelines for the prevention and treatment of type 2diabetes (2017 edition) also clearly indicate that the prevalence rate of DM in adults in China is as high as 10.9%. Among the numerous DM patients, Type 2diabetes mellitus (T2 DM) accounts for approximately 90% to 95% of the total DM. Research shows that patients suffering from T2DM are very likely to induce diseases such as coronary heart disease, cardiomyopathy, hypertension and hyperlipidemia, and have great harm to human bodies.
Since the etiology and pathogenesis of diabetes are not completely understood, there is currently a lack of effective etiological treatment. At present, the diabetes is clinically treated by mostly adopting insulin treatment and oral hypoglycemic drugs, however, diabetes belongs to a lifelong disease, long-term medication is needed, the injection administration method of insulin often brings inconvenience to patients, and clinically commonly used oral hypoglycemic drugs such as insulin secretagogues, biguanides, alpha-glycosidase inhibitors, thiazolidinedione derivatives, DPP-4 enzyme inhibitors and the like belong to chemical drugs or biological drugs, and adverse reactions such as gastrointestinal reactions, nausea, constipation, diarrhea, headache, dizziness, liver and kidney injuries and the like are caused after long-term administration, so that the tolerance and compliance of patients are reduced. In view of the above problems, it is very urgent to develop a safe, effective and blood sugar-lowering health food or functional beverage suitable for long-term administration in the current medical and health product market.
Disclosure of Invention
In order to overcome the defects of the existing diabetes treatment medicines, the invention provides a solution. China has abundant natural medicine resources and a long-term tea drinking culture, and the application history of natural medicines (such as traditional Chinese medicines) in traditional medicine is long-running, and nowadays, under the large background of modernization of traditional Chinese medicines, natural medicines are more and more favored by people due to the advantages of definite curative effect, high safety, low toxicity, low price and the like. Based on the reasons, the inventor develops a new tea bag with auxiliary hypoglycemic effect through long-term screening and repeated trial production, the tea bag is prepared by mulberry leaf tea, gymnema sylvestre, barley grass, guava, honeysuckle and medlar according to a certain weight proportion formula, the tea bag has scientific formula, the tea bag has the advantages of simple preparation process, convenience in drinking, safety and reliability, and has no obvious toxic effect on various observation indexes of male and female rats through safety toxicology tests, and effect verification tests prove that the tea bag can effectively improve various sugar metabolism indexes (including fasting blood glucose FBG, insulin level, C peptide, glucagon and the like) of a type 2diabetes model mouse (db/db mouse), 1000mL of drinking water is brewed in each tea bag, 200mL of 100 + one meal is drunk before each meal, and the tea bag has an obvious auxiliary treatment effect on type 2diabetes patients.
Specifically, the present invention is realized by the following technical means.
In a first aspect, the invention provides an auxiliary blood sugar reducing tea bag, which is prepared from the following raw materials in parts by weight:
30-40 parts of mulberry leaf tea, 20-25 parts of gymnema sylvestre, 20-25 parts of barley grass, 10-15 parts of guava, 5-10 parts of honeysuckle and 3-5 parts of wolfberry fruit.
Preferably, the auxiliary blood sugar reducing tea bag is prepared from the following raw materials in parts by weight:
33 parts of mulberry leaf tea, 22 parts of gymnema sylvestre, 21 parts of barley grass, 13 parts of guava, 7 parts of honeysuckle and 4 parts of wolfberry fruit.
The auxiliary blood sugar reducing tea bag is prepared from six raw materials, and the specific functions of the raw materials are as follows:
mulberry leaf tea: the folium Mori water extract can inhibit activity of maltase and lactase, and reduce absorption of above two kinds of sugar by organism. The folium Mori can promote insulin release and inhibit activity of alpha-glycosidase. The mulberry leaves can not only protect pancreas and promote normal secretion of insulin, but also improve hypertension and reduce cholesterol and triglyceride.
Guava: the guava contains high content of aromatic secondary metabolites (polyphenol compounds), which can improve the utilization rate of peripheral tissues to glucose and promote the combination of insulin and receptors, and in addition, the guava contains a large amount of chromium elements, so that chromium supplementation is helpful for improving the glucose tolerance of diabetics and people with abnormal glucose tolerance, reducing blood sugar and blood fat and enhancing the sensitivity of insulin.
A gymnema sylvestre: gymnema sylvestre has effects of lowering blood sugar, reducing blood lipid, resisting dental caries, inhibiting bacteria and regulating immunity. Gymnemic acid is a triterpenoid saponin substance separated from gymnema sylvestre, is a main bioactive component in gymnema sylvestre, and has various biological activities such as inhibition of small intestine absorption of oleic acid, inhibition of activity of glyceraldehyde triphosphate dehydrogenase, inhibition of protein synthesis, inhibition of activity of alpha-glucosidase, and inhibition of activity of sodium-dependent glucose transporter 1.
Barley seedling: as a nutritional crop, the barley seedling is often used for preparing health care products with the functions of resisting cancers, resisting oxidation, expelling toxin and delaying senility. In the research, the barley grass component is added into the blood sugar reducing tea bag according to a certain proportion, so that the effect of the tea bag on improving various sugar metabolism indexes of a type 2diabetes model mouse can be obviously improved, and the barley grass component and other components in the formula are judged to generate an active synergistic blood sugar reducing effect.
Honeysuckle flower: the honeysuckle is good for clearing away heat and toxic materials in the heart and stomach, contains quercetin, kaempferol, luteolin and other components, and the quercetin can improve INS-1 cell activity under high glucose stimulation, lower the relative expression quantity of BAX and PDX-1mRNA, inhibit INS-1 cell oxidative stress, reduce apoptosis and promote insulin secretion of beta cells; kaempferol can increase calcium flow in mitochondria under sugar stimulation, thereby promoting insulin secretion induced by glucose, and can promote insulin metabolism and secretion by regulating calcium absorption of mitochondria, and kaempferol can also prevent islet beta cells from oxidative damage or improve islet beta cell activity damaged by chronic hyperglycemia; luteolin can improve insulin beta cell damage induced by thapsigargin or uric acid, and improve glycolipid metabolism.
Wolfberry fruit: the medlar can increase the level of serum insulin, repair the damaged islet cells and enhance the sugar tolerance.
Furthermore, the invention also relates to application of the auxiliary blood sugar reducing tea bag in preparation of a medicine for treating type 2 diabetes.
Further, the invention also provides a preparation method of the auxiliary blood sugar reducing tea bag, which comprises the following steps:
(1) cleaning fresh mulberry leaves, deactivating enzyme with steam for 5min, controlling the temperature at 110-120 ℃, kneading for 5-10min after the deactivation of enzyme is completed, drying in a constant-temperature blast dryer at 40 ℃ until the water content is lower than 10%, then putting into a swing type traditional Chinese medicine crusher for crushing, and sieving with a 80-mesh sieve after crushing to obtain the mulberry leaf tea;
(2) cleaning Gymnema sylvestre, barley seedling, guava, honeysuckle and wolfberry fruit, respectively putting into a 40 ℃ constant-temperature blast drier or a 40 ℃ constant-temperature oven for drying until the water content is lower than 10%, respectively putting into a swing type traditional Chinese medicine crusher for crushing, and sieving by a 80-mesh sieve after crushing to obtain the raw tea powder of Gymnema sylvestre, barley seedling, guava, honeysuckle and wolfberry fruit;
(3) weighing the raw tea powder in corresponding parts by weight according to the formula, uniformly mixing, weighing 20-30g, and filling into a tea bag to obtain the auxiliary blood sugar reducing tea bag.
In a second aspect, the invention provides a functional solid beverage package for reducing blood sugar, which comprises 20-30g of the auxiliary blood sugar-reducing tea bag.
In a third aspect, the invention also provides a blood sugar reducing composition, which comprises the following raw materials in parts by weight:
30-40 parts of mulberry leaf tea, 20-25 parts of gymnema sylvestre, 20-25 parts of barley grass, 10-15 parts of guava, 5-10 parts of honeysuckle and 3-5 parts of wolfberry fruit.
In conclusion, the auxiliary blood sugar reducing tea bag is prepared from six raw materials, namely mulberry leaf tea, gymnema sylvestre, barley grass, guava, honeysuckle and wolfberry fruit, is mainly prepared from mulberry leaf tea, gymnema sylvestre and barley grass, is prepared from the guava, the honeysuckle and the wolfberry fruit, and has ideal auxiliary treatment effect on type 2diabetes under the synergistic effect. The tea bag can be drunk before a long-term meal, has the function of obviously reducing fasting and postprandial blood sugar and glucagon, and further realizes the purpose of improving the glycolipid metabolism of an organism. In addition, the tea bag has the advantages of convenience in taking, high safety, low price and the like, and is very suitable for the current market demand.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, it is obvious that the drawings in the following description are only specific embodiments mentioned for the present invention, and it is obvious for those skilled in the art that other drawings can be obtained according to the following drawings without inventive efforts.
FIG. 1 is a graph showing a comparison of fasting blood glucose levels between a blank control group and each example group before and after tea drinking.
Detailed Description
The technical solutions of the present invention are described below clearly and completely by specific examples, and it is obvious that the described embodiments are only some embodiments of the present invention, not all embodiments. Other advantages and features of the present invention will be readily apparent to those skilled in the art from the disclosure herein. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless otherwise defined, all technical terms used in the present invention have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, devices, and materials used in the examples, any methods, devices, and materials similar or equivalent to those described in the examples herein can be used in the practice of the invention in addition to the specific methods, devices, and materials used in the examples herein, in keeping with the knowledge of one skilled in the art and the description of the present invention.
In the invention, all parts and percentages are by weight unless otherwise specified, and all equipment and raw materials are commercially available or commonly used in the industry unless otherwise specified. The methods in the following examples are conventional in the art unless otherwise specified.
Example 1
An auxiliary blood sugar reducing tea bag is prepared from the following raw materials in parts by weight:
30 parts of mulberry leaf tea, 25 parts of gymnema sylvestre, 20 parts of barley grass, 10 parts of guava, 10 parts of honeysuckle and 5 parts of wolfberry fruit.
The preparation method comprises the following steps:
(1) cleaning fresh mulberry leaves, deactivating enzyme with steam for 5min at 120 deg.C, kneading for 10min, drying in 40 deg.C constant temperature blast drier until water content is less than 10%, pulverizing in a swing type traditional Chinese medicine pulverizer, and sieving with 80 mesh sieve to obtain mulberry leaf tea;
(2) cleaning Gymnema Yunnanense Tsiang, barley grass, guava, honeysuckle and medlar, respectively putting into a constant temperature oven at 40 ℃ for drying until the water content is lower than 10%, respectively putting into a swing type traditional Chinese medicine crusher for crushing, and sieving by a sieve of 80 meshes after crushing to obtain raw tea powder of Gymnema Yunnanense Tsiang, barley grass, guava, honeysuckle and medlar;
(3) weighing the raw tea powder according to the formula in corresponding parts by weight, uniformly mixing, weighing 25g, and filling into a tea bag to obtain the auxiliary blood sugar reducing tea bag, wherein 1 tea bag is taken each time and is added with boiling water for brewing for 12min, each tea bag is brewed with 1000mL of drinking water, and the volume of drinking water before each meal is 100-200 mL.
Example 2
An auxiliary blood sugar reducing tea bag is prepared from the following raw materials in parts by weight:
36 parts of mulberry leaf tea, 20 parts of gymnema sylvestre, 23 parts of barley grass, 12 parts of guava, 6 parts of honeysuckle and 3 parts of wolfberry fruit.
The preparation method is the same as example 1.
Example 3
An auxiliary blood sugar reducing tea bag is prepared from the following raw materials in parts by weight:
33 parts of mulberry leaf tea, 22 parts of gymnema sylvestre, 21 parts of barley grass, 13 parts of guava, 7 parts of honeysuckle and 4 parts of wolfberry fruit.
The preparation method is the same as example 1.
Example 4
Evaluation test for blood sugar reducing effect of auxiliary blood sugar reducing tea bag
(1) Grouping
Blank control group: purified water for brewing tea.
Example 1 group: 30 parts of mulberry leaf tea, 25 parts of gymnema sylvestre, 20 parts of barley grass, 10 parts of guava, 10 parts of honeysuckle and 5 parts of wolfberry fruit.
Example 2 group: 36 parts of mulberry leaf tea, 20 parts of gymnema sylvestre, 23 parts of barley grass, 12 parts of guava, 6 parts of honeysuckle and 3 parts of wolfberry fruit.
Example 3 group: 33 parts of mulberry leaf tea, 22 parts of gymnema sylvestre, 21 parts of barley grass, 13 parts of guava, 7 parts of honeysuckle and 4 parts of wolfberry fruit.
(2) Experimental animals and feeds
Experimental animals: db/db mice, male, four-week-old, supplied by Jiangsu Jiejiekang Biotech, having a weight of 20.82 + -1.57 g when purchased, and fed with SPF. The qualification number of the experimental animal: 202100532, license number: scxk (threo) 2018-.
Basic feed: 20g of flour, 10g of rice flour, 20g of corn, 25g of bran, 20g of bean material, 2g of bone meal, 2g of fish meal, 0.9g of salt and 0.1g of vitamin.
(3) Feeding and tea soup feeding mode
After the experimental animals are purchased, the basic feed is normally and adaptively fed for one week (SPF feeding, namely feeding the animals in animal rooms with the temperature of 23 +/-2 ℃, the humidity of 40-50 percent, artificial illumination and light and dark for 12 hours respectively). Then randomly divided into: blank control, example 1, example 2 and example 3. The blank control group does not carry out any treatment, and the blank control group drinks the purified water used for making tea for eating at a specific time and supplies the purified water without limitation; the auxiliary blood sugar reducing tea soup brewed according to the formula and the preparation method is drunk by the groups of the embodiments, and the auxiliary blood sugar reducing tea soup is eaten at a specific time and is eaten without limitation; continuously feeding for four weeks.
(4) Observation indicator and measurement method
During the test period, the body weight was weighed 1 time per week and appetite, behavior, feces, hair and animal death were observed. Fasting blood glucose was measured with a glucometer after 10h of fasting every week. Taking blood from heart of mouse by cutting spine after four weeks, placing whole blood in refrigerator at 4 deg.C for 30min, cooling to 4 deg.C in advance with low temperature centrifuge, centrifuging (3600r/min, 15min) to separate serum, carefully sucking upper layer serum, and storing in refrigerator at-80 deg.C. The contents of insulin, C-peptide and glucagon in the serum of mice were determined using a murine ELISA kit.
(5) Test results and comparative analysis
During the test period, db/db mice grow normally in body weight, move normally, have good mental status and do not die. After 28 days of administration, fasting plasma glucose levels and serum level analysis for each group of mice are shown in FIG. 1 and Table 1, respectively.
A comparison of fasting plasma glucose levels between the blank control group and the example group before and after drinking tea is shown in FIG. 1. As can be seen from fig. 1, there was no significant difference in fasting blood glucose between the example group before drinking tea and the blank control group, and the example 3 group had the best effect of lowering fasting blood glucose with increasing drinking time, and there was a significant difference from the blank control group (. about.p <0.01 was a significant difference, and. about.p <0.05 was a significant difference).
The effect on serum levels in db/db mice after 4 weeks of tea consumption is shown in Table 1. It can be seen that serum insulin and C-peptide were significantly elevated in the db/db mice of the example group compared to the blank control group, wherein the group of example 3 was very significantly different from the blank control group; glucagon was significantly reduced in the example group compared to the blank control group. The above results confirmed that the tea bag of the present invention has a significant hypoglycemic effect, and the group of example 3 was most excellent in reducing fasting plasma glucose and glucagon in mice, and increasing insulin and C-peptide to improve glycolipid metabolism.
TABLE 1 Effect on serum levels in db/db mice after 4 weeks of tea consumption
(significant difference is P <0.01, significant difference is P <0.05)
And (4) test conclusion: (1) in the example 1, the fasting blood sugar, the insulin and the C peptide have significant difference (P <0.05) with the blank control group, and have the function of assisting to reduce the blood sugar; in the example 2, the fasting blood sugar, the insulin, the C peptide and the glucagon in the group have significant difference (P <0.05) with the blank control group, and have the effect of significantly assisting in reducing the blood sugar; the results of the group 3, in which fasting plasma glucose, insulin, C-peptide and glucagon are significantly (P <0.05) or very significantly different (P <0.01) from the blank control group, showed more significant hypoglycemic effects, and all of the group 3 had hypoglycemic and glycolipid metabolism improving effects, with the group 3 being the best.
The tea soup of 3 groups of examples is taken, and safety toxicology tests show that the tea soup does not produce obvious toxic effect on various observation indexes of female and male rats, so that the tea soup is safe to take and does not cause toxic reaction.
The tea bag (or the pharmaceutical composition) can be taken alone to assist in reducing blood sugar, and can also be used in combination with blood sugar reducing drugs, such as metformin, acarbose, gliquidone tablets and the like, so as to enhance the blood sugar reducing effect of the blood sugar reducing drugs.
While the preferred embodiments and examples of the present invention have been described in detail, the present invention is not limited to the embodiments and examples, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art.
Claims (6)
1. The auxiliary blood sugar-reducing tea bag is characterized by being prepared from the following raw materials in parts by weight:
30-40 parts of mulberry leaf tea, 20-25 parts of gymnema sylvestre, 20-25 parts of barley grass, 10-15 parts of guava, 5-10 parts of honeysuckle and 3-5 parts of wolfberry fruit.
2. The auxiliary hypoglycemic tea bag of claim 1, wherein the weight parts of the raw materials are:
33 parts of mulberry leaf tea, 22 parts of gymnema sylvestre, 21 parts of barley grass, 13 parts of guava, 7 parts of honeysuckle and 4 parts of wolfberry fruit.
3. Use of the auxiliary blood glucose-lowering tea bag according to claim 1 or 2 in the preparation of a medicament for treating type 2 diabetes.
4. The preparation method of the auxiliary hypoglycemic tea bag according to claim 1 or 2, comprising the steps of:
(1) cleaning fresh mulberry leaves, deactivating enzyme with steam for 5min, controlling the temperature at 110-120 ℃, kneading for 5-10min after the deactivation of enzyme is completed, drying in a constant-temperature blast dryer at 40 ℃ until the water content is lower than 10%, then putting into a swing type traditional Chinese medicine crusher for crushing, and sieving with a 80-mesh sieve after crushing to obtain the mulberry leaf tea;
(2) cleaning Gymnema sylvestre, barley seedling, guava, honeysuckle and wolfberry fruit, respectively putting into a 40 ℃ constant-temperature blast drier or a 40 ℃ constant-temperature oven for drying until the water content is lower than 10%, respectively putting into a swing type traditional Chinese medicine crusher for crushing, and sieving by a 80-mesh sieve after crushing to obtain the raw tea powder of Gymnema sylvestre, barley seedling, guava, honeysuckle and wolfberry fruit;
(3) weighing the raw tea powder in corresponding parts by weight according to the formula, uniformly mixing, weighing 20-30g, and filling into a tea bag to obtain the auxiliary blood sugar reducing tea bag.
5. A functional solid beverage package for reducing blood sugar, which is characterized in that 20-30g of the auxiliary blood sugar reducing tea bag as claimed in claim 1 or 2 is contained in the functional solid beverage package for reducing blood sugar.
6. The blood sugar reducing composition is characterized by comprising the following raw materials in parts by weight:
30-40 parts of mulberry leaf tea, 20-25 parts of gymnema sylvestre, 20-25 parts of barley grass, 10-15 parts of guava, 5-10 parts of honeysuckle and 3-5 parts of wolfberry fruit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111575060.2A CN114190459A (en) | 2021-12-21 | 2021-12-21 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111575060.2A CN114190459A (en) | 2021-12-21 | 2021-12-21 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114190459A true CN114190459A (en) | 2022-03-18 |
Family
ID=80655940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111575060.2A Pending CN114190459A (en) | 2021-12-21 | 2021-12-21 | Auxiliary blood sugar-reducing tea bag and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114190459A (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005076750A2 (en) * | 2004-02-18 | 2005-08-25 | Lanson Biotech | A novel synergistic herbal formulation for diabetes cure |
CN101632404A (en) * | 2009-07-27 | 2010-01-27 | 深圳市千金方生物技术有限公司 | Blood sugar reducing healthy tea and preparation method thereof |
CN101779710A (en) * | 2010-02-11 | 2010-07-21 | 李寿山 | Ilex latifolia thumb bag having blood sugar-reducing, blood fat-reducing and blood pressure-reducing effects and method for preparing same |
CN101797000A (en) * | 2010-03-02 | 2010-08-11 | 浙江大学 | Preparation method of ultramicro mulberry leaf tea powder |
CN102652801A (en) * | 2011-03-03 | 2012-09-05 | 陕西诺华生物工程有限公司 | Chinese herbal medicine tea bag for lowering blood sugar and preventing diabetes mellitus complications |
CN103168882A (en) * | 2011-12-26 | 2013-06-26 | 镇江市丹徒区南山溪园茶叶专业合作社 | Health-care tea beneficial to reducing blood glucose and slowing down diabetic complications |
CN104336257A (en) * | 2014-10-28 | 2015-02-11 | 广西金昊生物科技有限公司 | Folium mori tea bag and preparation method thereof |
CN107319332A (en) * | 2017-05-23 | 2017-11-07 | 广州市高纤宝健康食品有限公司 | A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof |
CN109745359A (en) * | 2019-03-08 | 2019-05-14 | 储殷 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
-
2021
- 2021-12-21 CN CN202111575060.2A patent/CN114190459A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005076750A2 (en) * | 2004-02-18 | 2005-08-25 | Lanson Biotech | A novel synergistic herbal formulation for diabetes cure |
CN101632404A (en) * | 2009-07-27 | 2010-01-27 | 深圳市千金方生物技术有限公司 | Blood sugar reducing healthy tea and preparation method thereof |
CN101779710A (en) * | 2010-02-11 | 2010-07-21 | 李寿山 | Ilex latifolia thumb bag having blood sugar-reducing, blood fat-reducing and blood pressure-reducing effects and method for preparing same |
CN101797000A (en) * | 2010-03-02 | 2010-08-11 | 浙江大学 | Preparation method of ultramicro mulberry leaf tea powder |
CN102652801A (en) * | 2011-03-03 | 2012-09-05 | 陕西诺华生物工程有限公司 | Chinese herbal medicine tea bag for lowering blood sugar and preventing diabetes mellitus complications |
CN103168882A (en) * | 2011-12-26 | 2013-06-26 | 镇江市丹徒区南山溪园茶叶专业合作社 | Health-care tea beneficial to reducing blood glucose and slowing down diabetic complications |
CN104336257A (en) * | 2014-10-28 | 2015-02-11 | 广西金昊生物科技有限公司 | Folium mori tea bag and preparation method thereof |
CN107319332A (en) * | 2017-05-23 | 2017-11-07 | 广州市高纤宝健康食品有限公司 | A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof |
CN109745359A (en) * | 2019-03-08 | 2019-05-14 | 储殷 | Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
罗明等: "桑叶不同有效部位对2型糖尿病大鼠的降糖作用", 《中国医院药学杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5242567B2 (en) | Anti-diabetic composition containing chicory acid and / or one of its metabolites | |
CN103637197A (en) | Propolis soft capsule and preparation method thereof | |
CN102551065B (en) | Blood sugar reducing food series | |
JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
JP2012207009A (en) | Method for producing mulberry twig pulverized powder | |
CN109123627A (en) | A kind of health food with effect of weight reducing | |
CN108420065A (en) | A kind of antihypelipidemic product rich in bitter gourd polypeptide | |
KR20160007728A (en) | Method for manufacturing garlic skin extract and food composition for preventing and alleviating diabetes prepared using the same | |
CN103380842B (en) | Method for preparing health care morning tea by utilizing whole plant powder of mung beans | |
CN110624042B (en) | Composition for treating diabetic diseases | |
JP5064652B2 (en) | Diabetes prevention and treatment composition and health food containing active ingredients thereof | |
JP5344494B2 (en) | Lipid metabolism improving agent, functional food, food additive, antioxidant, medicine, arteriosclerosis preventive / improving agent, cosmetics, and method for producing lipid metabolism improving agent | |
CN107580496A (en) | The anti-glycosuria effect of gypenoside 75 | |
JP2021508433A (en) | Carob fruit composition and its preparation method and application | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
CN111281902A (en) | Application of lithocarpus litseifolius or active extract thereof | |
KR20130104132A (en) | Composition for suppressing elevation of blood sugar level comprising onion coat extract and manufacturing method of onion coat extract | |
CN114190459A (en) | Auxiliary blood sugar-reducing tea bag and preparation method thereof | |
CN105517550A (en) | Characterization of rice | |
JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
UA112174C2 (en) | METHOD OF GETTING HERBAL EXTRACT | |
TW202034790A (en) | Bitter gourd peptide composition | |
CN104798935A (en) | Health-care and health-preservation tea and preparation method thereof | |
KR102099559B1 (en) | Composition for preventing or treating diabetes and method for manufacturing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220318 |